Business
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refr
About this update from Bioatla, Inc.
[{"type":"image","alt":"BioAtla, Inc.","displaySize":"","headline":null,"caption":"BioAtla, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":164,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/add243e63c7c504df7517ccebf39d348"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z8G3hxIezptosVzATIpKBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTk2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/add243e63c7c504df7517ccebf39d348","width":164,"height":75}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 ","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care ","length":249,"tagName":"p"}]},{"val":[{"type":"text","content":"Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitors","length":236,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash balance of $49mm at year-end 2024 with recent cost-reduction measures expected to further extend runway beyond key clinical readouts in 1H 2026","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Management to host conference call and webcast today at 4:30 PM Eastern Time ","length":76,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":862,"olType":false},{"type":"text","content":"SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided highlights on its clinical programs.","length":394,"tagName":"p"},{"type":"text","content":"“We are encouraged by the differentiated clinical outcomes observed in our evolving CAB platform program datas...